
Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the burden of itch in atopic dermatitis, and why JAK inhibitors may be able to provide relief.

Raj Chovatiya, MD, PhD, MSCI, is a clinical associate professor at Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, and Dermatology Times' editor in chief emeritus (Fall 2024).

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, explore the burden of itch in atopic dermatitis, and why JAK inhibitors may be able to provide relief.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, talk about the use of oral systemic agents and what they’ve learned about the patient experience from the use of these agents.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, examine the clinical context for the approval of topical ruxolitinib and its role in the treatment armamentarium.

Thought leaders discuss why JAK inhibitors are well suited for the management of itch and inflammation in the treatment of moderate to severe atopic dermatitis.

Raj Chovatiya, MD, PhD, and Lisa Swanson, MD, FAAD, review the recent trajectory of the atopic dermatitis therapeutic spectrum, notably how several newer approvals have changed how clinicians approach treatment.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, provide take-home messages for dermatologists treating pediatric patients with atopic dermatitis.

Atopic dermatitis specialists discuss how to have a conversation with parents about risks of biologics and how to answer questions about length of therapy.

Expert pediatric dermatologists provide impressions on the case of a 12-year-old girl with atopic dermatitis.

Joshua Zeichner, MD, reviews the case of a 12-year-old girl with atopic dermatitis.

Expert pediatric dermatologists discuss the importance of combination therapy and shared decision-making when treating pediatric patients with atopic dermatitis.

Brittany Craiglow, MD, and Joshua Zeichner, MD, discuss treatment adherence in pediatric patients with atopic dermatitis.

Vikash Oza, MD, provides clinical insight for Case 2, a 7-year-old female patient with atopic dermatitis.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; and Vikash Oza, MD, address techniques for injectables when treating pediatric patients with atopic dermatitis.

Dr Joshua Zeichner reviews the case of a 7-year-old female patient with atopic dermatitis.

Joshua Zeichner, MD; Brittany Craiglow, MD; Elizabeth Swanson, MD; Vikash Oza, MD; and Raj Chovatiya, MD, PhD, discuss treatments beyond topical agents and the use of dupilumab in pediatric patients with atopic dermatitis.

Expert pediatric dermatologists Drs Elizabeth Swanson, Joshua Zeichner, and Raj Chovatiya share impressions from patient case No. 1.

Dr Joshua Zeichner reviews the case of a 2-year-old patient with atopic dermatitis.

Experts treating pediatric atopic dermatitis discuss the pharmacological options for the treatment of pediatric atopic dermatitis.

Expert pediatric dermatologists Elizabeth Swanson, MD, and Joshua Zeichner, MD, discuss the burden of pediatric atopic dermatitis.

Brittany Craiglow, MD; Raj Chovatiya, MD, PhD; and Joshua Zeichner, MD, discuss the presentation of pediatric patients with atopic dermatitis and how to properly assess and diagnose pediatric patients’ atopic dermatitis.

Elizabeth Swanson, MD, and Joshua Zeichner, MD, discuss the psychological factors impacting pediatric patients’ atopic dermatitis.

Joshua Zeichner, MD, and Raj Chovatiya, MD, PhD, dive deep into the pathogenesis of atopic dermatitis and discuss how agents treating atopic dermatitis work.

Joshua Zeichner, MD, and Vikash Oza, MD, discuss characteristics of type 2 inflammation and the impact of itching on pediatric patients with atopic dermatitis.

Education, honesty, and communication skills are key for both patient and dermatologist when it comes to creating treatment regimens.

Fresh spins on established treatments and newly FDA-approved drugs and devices provide a framework for changing therapies and modalities for acne regimens.

Take a world tour of the global game-changing advances and home-grown success strategies dermatologists in the United States and abroad are using to tackle the challenges of acne.